ELISA/assay

Human Glucosylceramidase, GBA ELISA Kit

MBS922515

48-Strip-Wells

510 USD

ELISA Kit

Human Glucosylceramidase, GBA ELISA Kit

glucosidase, beta; acid (includes glucosylceramidase)

Human Glucosylceramidase (GBA) ELISA kit; GBA1; GCB; GLUC; D-glucosyl-N-acylsphingosine glucohydrolase; beta-glucocerebrosidase; glucocerebrosidase; lysosomal glucocerebrosidase; glucosidase; beta; acid (includes glucosylceramidase)

glucosylceramidase isoform 1; Glucosylceramidase; glucosylceramidase; beta-GC; alglucerase; imiglucerase; acid beta-glucosidase; beta-glucocerebrosidase; lysosomal glucocerebrosidase; glucosylceramidase-like protein; D-glucosyl-N-acylsphingosine glucohydrolase; glucosidase, beta, acid; Acid beta-glucosidase; Alglucerase; Beta-glucocerebrosidase; Beta-GC; D-glucosyl-N-acylsphingosine glucohydrolase; Imiglucerase

GBA

GBA; GBA; GCB; GBA1; GLUC; GC; GLUC; Beta-GC

GLCM_HUMAN

Human

536

This assay has high sensitivity and excellent specificity for detection of human GBA. No significant cross-reactivity or interference between human GBA and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Samples: Serum, plasma, tissue homogenates. Assay Type: Sandwich. Detection Range: 0.312 ng/ml -20 ng/ml. Sensitivity: The minimum detectable dose of human GBA is typically less than 0.078 ng/ml.The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest protein concentration that could be differentiated from zero. It was determined the mean O.D value of 20 replicates of the zero standard added by their three standard deviations.

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV%<8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision: Inter-assay Precision (Precision between assays): CV%<10%. Three samples of known concentration were tested in twenty assays to assess.

Principle of the Assay: This assay employs the quantitative sandwich enzyme immunoassay technique. Antibody specific for GBA has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any GBA present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for GBA is added to the wells. After washing, avidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of GBA bound in the initial step. The color development is stopped and the intensity of the color is measured.

54607043

NP_000148.2

NM_000157.3

P04062

59,716 Da

Glycosphingolipid Metabolism Pathway (530751); Lysosome Pathway (99052); Lysosome Pathway (96865); Metabolism Pathway (477135); Metabolism Of Lipids And Lipoproteins Pathway (160976); Other Glycan Degradation Pathway (82976); Other Glycan Degradation Pathway (346); Sphingolipid Metabolism Pathway (82994); Sphingolipid Metabolism Pathway (119543); Sphingolipid Metabolism Pathway (369)

This gene encodes a lysosomal membrane protein that cleaves the beta-glucosidic linkage of glycosylceramide, an intermediate in glycolipid metabolism. Mutations in this gene cause Gaucher disease, a lysosomal storage disease characterized by an accumulation of glucocerebrosides. A related pseudogene is approximately 12 kb downstream of this gene on chromosome 1. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2010]

GBA: Defects in GBA are the cause of Gaucher disease (GD); also known as glucocerebrosidase deficiency. GD is the most prevalent lysosomal storage disease, characterized by accumulation of glucosylceramide in the reticulo-endothelial system. Different clinical forms are recognized depending on the presence (neuronopathic forms) or absence of central nervous system involvement, severity and age of onset. Defects in GBA are the cause of Gaucher disease type 1 (GD1); also known as adult non-neuronopathic Gaucher disease. GD1 is characterized by hepatosplenomegaly with consequent anemia and thrombopenia, and bone involvement. The central nervous system is not involved. Defects in GBA are the cause of Gaucher disease type 2 (GD2); also known as acute neuronopathic Gaucher disease. GD2 is the most severe form and is universally progressive and fatal. It manifests soon after birth, with death generally occurring before patients reach two years of age. Defects in GBA are the cause of Gaucher disease type 3 (GD3); also known as subacute neuronopathic Gaucher disease. GD3 has central nervous manifestations. Defects in GBA are the cause of Gaucher disease type 3C (GD3C); also known as pseudo-Gaucher disease or Gaucher-like disease. Defects in GBA are the cause of Gaucher disease perinatal lethal (GDPL). It is a distinct form of Gaucher disease type 2, characterized by fetal onset. Hydrops fetalis, in utero fetal death and neonatal distress are prominent features. When hydrops is absent, neurologic involvement begins in the first week and leads to death within 3 months. Hepatosplenomegaly is a major sign, and is associated with ichthyosis, arthrogryposis, and facial dysmorphism. Perinatal lethal Gaucher disease is associated with non-immune hydrops fetalis, a generalized edema of the fetus with fluid accumulation in the body cavities due to non-immune causes. Non-immune hydrops fetalis is not a diagnosis in itself but a symptom, a feature of many genetic disorders, and the end-stage of a wide variety of disorders. Defects in GBA contribute to susceptibility to Parkinson disease (PARK). A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features. Belongs to the glycosyl hydrolase 30 family. 3 isoforms of the human protein are produced by alternative splicing. Protein type: Hydrolase; EC 3.2.1.45; Lipid Metabolism - sphingolipid; Glycan Metabolism - other glycan degradation. Chromosomal Location of Human Ortholog: 1q21. Cellular Component: lysosomal lumen; lysosomal membrane. Molecular Function: protein binding; receptor binding; glucosylceramidase activity. Biological Process: glucosylceramide catabolic process; negative regulation of MAP kinase activity; sphingolipid metabolic process; skin morphogenesis; response to glucocorticoid stimulus; response to testosterone stimulus; positive regulation of protein amino acid dephosphorylation; regulation of water loss via skin; response to estrogen stimulus; negative regulation of inflammatory response; carbohydrate metabolic process; sphingosine biosynthetic process; negative regulation of interleukin-6 production; ceramide biosynthetic process; glycosphingolipid metabolic process; response to pH. Disease: Gaucher Disease, Type Ii; Dementia, Lewy Body; Parkinson Disease, Late-onset; Gaucher Disease, Perinatal Lethal; Gaucher Disease, Type Iiic; Gaucher Disease, Type Iii; Gaucher Disease, Type I

48-Strip-Wells

510 USD

96-Strip-Wells

725

5x96-Strip-Wells

2565

10x96-Strip-Wells

4800